My Account

Risk Management
Workers Comp & Safety
Employee Benefits
International
People
Events
BI Intelligence
Magazine
- Current Issue
- Past Issues
DEI Institute

Recent Quotes

View Full List

My Watchlist

Indicators

Business Insurance Index

Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

161.66 +1.60 (+1.00%)

Streaming Delayed Price Updated: 1:55 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

55 56 Next >

The Byzantine Adderall Shortage Puts Teva And Others In The Hot Seat ↗

April 05, 2023

Millions of people are scrambling to get their ADHD medication. Here's why.

Via Investor's Business Daily

Stock Market Rallies On Micron, Alibaba, Lululemon, Ebbing Bank Fears: Weekly Review ↗

March 31, 2023

The stock market rallied on ebbing bank fears and positive news from Micron, Alibaba and Lululemon Athletica.

Via Investor's Business Daily

What Bear Market? These 2 Winning Stocks Are Still Worth Buying. ↗

March 30, 2023

These two pharma stocks are rock-solid picks in any kind of market.

Via The Motley Fool

Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 27, 2023

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider.

Via Benzinga

FDA Approves Pharming's Immune Disorder Drug, As First APDS Therapy ↗

March 27, 2023

Via Benzinga

Elon Musk-Led Neuralink Seeks Human Trial Collaborators, Credit Suisse May Face Disciplinary Action, First Citizens Takeover Silicon Valley Bank: Today's Top Stories ↗

March 27, 2023

Benzinga

Via Benzinga

Novartis Surges As It Goes After Eli Lilly's Second Biggest Moneymaker ↗

March 27, 2023

The battle in early-stage breast cancer is heating up as Novartis enters the ring.

Via Investor's Business Daily

Why Novartis Shares Are Trading Higher Premarket Today ↗

March 27, 2023

Novartis AG (NYSE: NVS) shares are trading higher in the premarket session after its breast cancer drug showed clinical benefit in early-stage breast cancer.

Via Benzinga

First Republic Bank, KeyCorp And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

March 27, 2023

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

How Is The Market Feeling About Novartis? ↗

March 21, 2023

Via Benzinga

FDA Approves Novartis' Tafinlar + Mekinist For Pediatric Brain Cancer With Certain Mutations ↗

March 17, 2023

Via Benzinga

New research project aims to set standardized approach to lipoprotein(a) management

March 24, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

2 Biotech Stocks That Could Make You Richer ↗

March 21, 2023

One is a well-established, large-cap drugmaker, while the other is still making a name for itself in the industry.

Via The Motley Fool

Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo ↗

March 20, 2023

Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days.

Via Benzinga

Novartis Reveals Long-Term Data Of Atrophy Gene Therapy Exhibiting Sustained Durability Of Up To 7.5 Years ↗

March 20, 2023

Via Benzinga

Elon Musk Frets As Microsoft Axes AI Ethics Team, Richard Branson's Virgin Orbit Stops Ops, Credit Suisse To Borrow Up To $54B: Today's Top Stories ↗

March 16, 2023

Benzinga

Via Benzinga

Novartis' Prostate Cancer Therapy Hit By Supply Crunch, Seeks To Ramp Up Production To Ease Supply Issues ↗

March 16, 2023

Last week the FDA said Novartis AG's (NYSE: NVS) Pluvicto is short in supply due to manufacturing and delivery issues. Pluvicto is a radiopharmaceutical medication used for prostate-specific membrane...

Via Benzinga

Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb

March 14, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival...

Via FinancialNewsMedia

3 High Dividend Stocks With Attractive Total Return Potential ↗

March 10, 2023

In the current economic environment, it is crucial for investors to prioritize quality, reliable dividend stocks and high total returns.

Via InvestorPlace

Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?

March 08, 2023

Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?

Via News Direct

Topics Economy

Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?

March 08, 2023

By David Willey, Benzinga

Via TheNewswire.com

Topics Economy

Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? ↗

March 07, 2023

Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics.

Via Benzinga

4 AI Stocks That Are Revolutionizing Healthcare ↗

March 06, 2023

With the growing use of AI in healthcare, it has led to a number of stocks that are focused on this industry.

Via InvestorPlace

This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier? ↗

March 03, 2023

Texas-based biotech company, Coya Therapeutics (NASDAQ: COYA), is positioning itself as a leader in a promising area of the medical field.

Via Benzinga

Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca ↗

February 25, 2023

Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between...

Via Talk Markets

Novartis Takes Down $80M NASH Pact With Pliant Therapeutics ↗

February 24, 2023

Via Benzinga

Better Buy: Beam Therapeutics or Intellia Therapeutics? ↗

February 22, 2023

The two clinical-stage gene-editing companies have good long-term prospects.

Via The Motley Fool

Lupus Therapeutics Market Is on the Verge of Crossing at High CAGR of 9% in 2022-2029

February 21, 2023

The global lupus therapeutics market is expected to reach a CAGR of 9% during the forecast period (2022-2029).

Via SBWire

Bladder Prolapse (Cystocele) Market to Touch at High CAGR of 8.3% by 2022-2029

February 20, 2023

Bladder Prolapse (cystocele) Market is expected to grow at a CAGR of 8.3 % during the forecast period (2022-2029).

Via SBWire

Choroidal Neovascularization Market Share Size Trends Overview Analysis 2022-2029

February 16, 2023

Global Choroidal Neovascularization Market to Witness Huge Growth by Key Players: Bausch Health Companies Inc, Bayer AG, Gilead Sciences Inc, F.Hoffmann –La Roche AG,MaaT Pharma Novartis AG, Pfizer...

Via SBWire

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

55 56 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.

Information

About Us
Contact
Advertise
Privacy Policy
Terms & Condition